Analyst Price Targets — PRCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2026 6:03 pm | Richard Newitter | Truist Financial | $30.00 | $22.69 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $30 at Truist Securities |
| February 26, 2026 10:58 am | Nathan Treybeck | Wells Fargo | $34.00 | $27.84 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $34 at Wells Fargo |
| December 18, 2025 2:14 pm | Richard Newitter | Truist Financial | $47.00 | $34.24 | TheFly | Procept BioRobotics price target lowered to $47 from $50 at Truist |
| December 12, 2025 5:57 am | Danielle Antalffy | UBS | $62.00 | $36.02 | StreetInsider | UBS Starts Procept BioRobotics Corp (PRCT) at Buy |
| December 2, 2025 11:34 am | Patrick Wood | Morgan Stanley | $51.00 | $30.41 | TheFly | Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley |
| November 5, 2025 2:23 pm | Matt O'Brien | Piper Sandler | $50.00 | $32.80 | TheFly | Procept BioRobotics price target lowered to $50 from $55 at Piper Sandler |
| November 5, 2025 11:19 am | Mike Kratky | Leerink Partners | $55.00 | $35.02 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $55 at Leerink Partners |
| November 5, 2025 11:18 am | — | Wells Fargo | $51.00 | $35.02 | TheFly | Procept BioRobotics price target lowered to $51 from $58 at Wells Fargo |
| October 15, 2025 12:46 pm | — | Truist Financial | $50.00 | $34.11 | TheFly | Procept BioRobotics price target lowered to $50 from $64 at Truist |
| September 2, 2025 10:05 am | Suraj Kalia | Oppenheimer | $60.00 | $41.58 | StreetInsider | Oppenheimer Upgrades Procept BioRobotics Corp (PRCT) to Outperform |
Latest News for PRCT
Artisan Partners Limited Partnership grew its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by 38.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,365,099 shares of the company's stock after acquiring an additional 378,844 shares during
MILWAUKEE, Feb. 26, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics (NASDAQ: PRCT). The investigation results from inaccurate statements PROCEPT BioRobotics may have made regarding its financial statements, business operations and prospects.
PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript
Procept Biorobotics stock crashed Thursday on a hard-to-stomach update that included light fourth-quarter sales and a 2026 guidance cut.
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goals, and 2026 - 2027 financial guidance.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRCT.
U.S. House Trading
No House trades found for PRCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.